Overview

Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent
Phase:
Phase 3
Details
Lead Sponsor:
American Regent, Inc.
Luitpold Pharmaceuticals
Treatments:
Ferric Compounds
Ferric gluconate
Iron-Dextran Complex